Christine M. Eng

Christine M. Eng

Auto-generated profile, based on publicly available information

Christine M. Eng

Baylor College of Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
YYYaping Yang
Yaping Yang
DMDonna M. Muzny
Donna M. Muzny
JRJeffrey G. Reid
Jeffrey G. Reid
MBMatthew N. Bainbridge
Matthew N. Bainbridge
AWAlecia Willis
Alecia Willis
CEChristine M. Eng
Christine M. Eng
Whole-exome sequencing is a diagnostic approach for the identification of molecular defects in patients with suspected genetic disorders. We developed technical, bioinformatic, interpretive, and validation pipelines for whole-exome sequencing in a certified clinical laboratory to identify sequence variants underlying disease phenotypes in patients. We present data on the first 250 probands for whom referring physicians ordered whole-exome sequencing. Patients presented with a range of phenotypes suggesting potential genetic causes. Approximately 80% were children with neurologic phenotypes. Insurance coverage was similar to that for established genetic tests. We identified 86 mutated alleles that were highly likely to be causative in 62 of the 250 patients, achieving a 25% molecular diagnostic rate (95% confidence interval, 20 to 31). Among the 62 patients, 33 had autosomal dominant disease, 16 had autosomal recessive disease, and 9 had X-linked disease. A total of 4 probands received two nonoverlapping molecular diagnoses, which potentially challenged the clinical diagnosis that had been made on the basis of history and physical examination. A total of 83% of the autosomal dominant mutant alleles and 40% of the X-linked mutant alleles occurred de novo. Recurrent clinical phenotypes occurred in patients with mutations that were highly likely to be causative in the same genes and in different genes responsible for genetically heterogeneous disorders. Whole-exome sequencing identified the underlying genetic defect in 25% of consecutive patients referred for evaluation of a possible genetic condition. (Funded by the National Human Genome Research Institute.)

12 November 2014 in JAMA
Verified
Journal Article
Open access
PDF file
YYYaping Yang
Yaping Yang
DMDonna M. Muzny
Donna M. Muzny
FXFan Xia
Fan Xia
ZNZhiyv Niu
Zhiyv Niu
RPRichard Person
Richard Person
CEChristine M. Eng
Christine M. Eng
We previously reported a molecular diagnosis rate of 25% for the first 250 patients without prior diagnosis who were referred to our diagnostic laboratory for whole-exome sequencing.1 Quiz Ref ID Whole-exome sequencing analyzes the exons or coding regions of thousands of genes simultaneously using next-generation sequencing techniques. By sequencing the exome of a patient and comparing it with a normal reference sequence, variations in an individual’s DNA sequence can be identified and related back to the individual’s medical concerns in an effort to discover the cause of the medical disorder. The overall molecular diagnostic rate was higher than several other comparable genetic tests, including chromosome studies (5%-10%)2,3 and chromosomal microarray analysis (15%-20%).4 Notably, in 4 separate cases, molecular findings were reported for 2 Mendelian disorders in the same patient, with clinical features characteristic of the 2 different Mendelian disorders. Secondary (incidental) findings were also observed at a low rate.1,5-7

28 September 2018 in Genome Medicine
Verified
Journal Article
Open access
PDF file
ENElizabeth A. Normand
Elizabeth A. Normand
ABAlicia Braxton
Alicia Braxton
SNSalma Nassef
Salma Nassef
PWPatricia A. Ward
Patricia A. Ward
FVFrancesco Vetrini
Francesco Vetrini
YYYaping Yang
Yaping Yang
Exome sequencing is now being incorporated into clinical care for pediatric and adult populations, but its integration into prenatal diagnosis has been more limited. One reason for this is the paucity of information about the clinical utility of exome sequencing in the prenatal setting. We retrospectively reviewed indications, results, time to results (turnaround time, TAT), and impact of exome results for 146 consecutive “fetal exomes” performed in a clinical diagnostic laboratory between March 2012 and November 2017. We define a fetal exome as one performed on a sample obtained from a fetus or a product of conception with at least one structural anomaly detected by prenatal imaging or autopsy. Statistical comparisons were performed using Fisher’s exact test. Prenatal exome yielded an overall molecular diagnostic rate of 32% (n = 46/146). Of the 46 molecular diagnoses, 50% were autosomal dominant disorders (n = 23/46), 41% were autosomal recessive disorders (n = 19/46), and 9% were X-linked disorders (n = 4/46). The molecular diagnostic rate was highest for fetuses with anomalies affecting multiple organ systems and for fetuses with craniofacial anomalies. Out of 146 cases, a prenatal trio exome option designed for ongoing pregnancies was performed on 62 fetal specimens, resulting in a diagnostic yield of 35% with an average TAT of 14 days for initial reporting (excluding tissue culture time). The molecular diagnoses led to refined recurrence risk estimates, altered medical management, and informed reproductive planning for families. Exome sequencing is a useful diagnostic tool when fetal structural anomalies suggest a genetic etiology, but other standard prenatal genetic tests did not provide a diagnosis.

27 June 2013 in Genome Medicine
Verified
Journal Article
Open access
PDF file
JLJames Lupski
James Lupski
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
YYYaping Yang
Yaping Yang
MBMatthew N Bainbridge
Matthew N Bainbridge
SJShalini Jhangiani
Shalini Jhangiani
RGRichard A Gibbs
Richard A Gibbs
Background: The debate regarding the relative merits of whole genome sequencing (WGS) versus exome sequencing (ES) centers around comparative cost, average depth of coverage for each interrogated base, and their relative efficiency in the identification of medically actionable variants from the myriad of variants identified by each approach. Nevertheless, few genomes have been subjected to both WGS and ES, using multiple next generation sequencing platforms. In addition, no personal genome has been so extensively analyzed using DNA derived from peripheral blood as opposed to DNA from transformed cell lines that may either accumulate mutations during propagation or clonally expand mosaic variants during cell transformation and propagation. Methods: We investigated a genome that was studied previously by SOLiD chemistry using both ES and WGS, and now perform six independent ES assays (Illumina GAII (x2), Illumina HiSeq (x2), Life Technologies' Personal Genome Machine (PGM) and Proton), and one additional WGS (Illumina HiSeq). Results: We compared the variants identified by the different methods and provide insights into the differences among variants identified between ES runs in the same technology platform and among different sequencing technologies. We resolved the true genotypes of medically actionable variants identified in the proband through orthogonal experimental approaches. Furthermore, ES identified an additional SH3TC2 variant (p.M1?) that likely contributes to the phenotype in the proband. Conclusions: ES identified additional medically actionable variant calls and helped resolve ambiguous single nucleotide variants (SNV) documenting the power of increased depth of coverage of the captured targeted regions. Comparative analyses of WGS and ES reveal that pseudogenes and segmental duplications may explain some instances of apparent disease mutations in unaffected individuals.

1 September 2008 in Human Mutation
Verified
Journal Article
Closed access
PDF file
DGDaniela del Gaudio
Daniela del Gaudio
YYYaping Yang
Yaping Yang
BBBarbara A. Boggs
Barbara A. Boggs
ESEric S. Schmitt
Eric S. Schmitt
JLJennifer A. Lee
Jennifer A. Lee
CEChristine M. Eng
Christine M. Eng
The dystrophinopathies, which include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X‐linked dilated cardiomyopathy, are X‐linked recessive neuromuscular disorders caused by mutations in the dystrophin gene (DMD). Approximately 70% of mutations causing DMD/BMD are deletions or duplications and the remainder are point mutations. Current clinical diagnostic strategies have limits of resolution that make detection of small DMD deletions and duplications difficult to identify. We developed an oligonucleotide‐based array comparative genomic hybridization (array‐CGH) platform for the enhanced identification of deletions and duplications in the DMD gene. Using this platform, 39 previously characterized patient samples were analyzed, resulting in the accurate identification of 38 out of 39 rearrangements. Array‐CGH did not identify a 191‐bp deletion partially involving exon 19 that created a junction fragment detectable by Southern hybridization. To further evaluate the sensitivity and specificity of this array, we performed concurrent blinded analyses by conventional methodologies and array‐CGH of 302 samples submitted to our clinical laboratory for DMD deletion/duplication testing. Results obtained on the array‐CGH platform were concordant with conventional methodologies in 300 cases, including 69 with clinically‐significant rearrangements. In addition, the oligonucleotide array‐CGH platform detected two duplications that conventional methods failed to identify. Five copy‐number variations (CNVs) were identified; small size and location within introns predict the benign nature of these CNVs with negligible effect on gene function. These results demonstrate the utility of this array‐CGH platform in detecting submicroscopic copy‐number changes involving the DMD gene, as well as providing more precise breakpoint identification at high‐resolution and with improved sensitivity. Hum Mutat 29(9), 1100–1107, 2008.

6 July 2011 in International Journal of Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
MMMeenal S Mendiratta
Meenal S Mendiratta
YYYaping Yang
Yaping Yang
ABAndrea E Balazs
Andrea E Balazs
AWAlecia S Willis
Alecia S Willis
CEChristine M Eng
Christine M Eng
LPLorraine Potocki
Lorraine Potocki
Isolated hypocortisolism due to ACTH deficiency is a rare condition that can be caused by homozygous or compound heterozygous mutations in the gene encoding proopiomelanocortin (POMC). Loss of function mutations of POMC gene typically results in adrenal insufficiency, obesity and red hair. We describe an 18 month old Hispanic female with congenital adrenal insufficiency, a novel POMC mutation and atypical clinical features. The patient presented at the age of 9 months with hypoglycemia and the endocrine evaluation resulted in a diagnosis of ACTH deficiency. She developed extreme weight gain prompting sequence analysis of POMC, which revealed a homozygous c.231C > A change which is predicted to result in a premature termination codon. The case we report had obesity, hypocortisolism but lacked red hair which is typical for subjects with POMC mutations. Mutations of POMC should be considered in individuals with severe early onset obesity and adrenal insufficiency even when they lack the typical pigmentary phenotype.